|
|
|
| Relationship between serum HMGB1 and sTLT-1 levels and adverse cardiovascular events after percutaneous coronary intervention in patients with acute myocardial infarction |
| LIANG Chunfang1 CHEN Zihui2 DONG Yanzhang1 |
1.Department of Emergency, the Fourth People′s Hospital of Langfang City of Hebei Province, Hebei Province, Langfang 065700, China;
2.Department of General Surgery, the Fourth People′s Hospital of Langfang City of Hebei Province, Hebei Province, Langfang 065700, China |
|
|
|
Abstract Objective To investigate the relationship between serum high-mobility group box-1 (HMGB1) and soluble triggering receptor expressed on myeloid cells-like transcript-1 (sTLT-1) levels and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods From March 2016 to March 2018, 198 cases with AMI patients after PCI admitted to the Fourth People′s Hospital of Langfang City of Hebei Province were selected. According to the whether or not MACE happens, they were divided into MACE group (n = 57) and non-MACE group (n = 141). The control group included 50 patients who had no history of AMI and acute or chronic infection. Heart rate (HR), Killip cardiac function grading, operation time, serum levels of cholesterol, glycosylated hemoglobin (HbA1c), HMGB1, sTLT-1, high-sensitivity C-reactive protein (hs-CRP) and cardiac troponin I (cTnI) were compared among the three groups. Risk factors of MACE after PCI in AMI patients and correlation analysis between HMGB1, sTLT-1 levels and hs-CRP, cTnI levels were analyzed. ROC curve was used to evaluate the predictive value of serum HMGB1 and sTLT-1 for the occurrence of MACE after operation. Results There were no statistical significance differences in HR, Killip cardiac function grading, operation time, HbA1c and cholesterol among the three groups (all P > 0.05). The levels of HMGB1, sTLT-1, hs-CRP and cTnI in MACE group and non-MACE group were higher than those in control group, the levels of HMGB1, sTLT-1, hs-CRP and cTnI in MACE group were higher than those in non-MACE group, and the differences were statistically significant (all P < 0.05). Logistic regression analysis showed that HMGB1 sTLT-1, hs-CRP and cTnI levels were independent risk factors for MACE after PCI in AMI patients. After PCI, serum HMGB1 levels in AMI patients were positively correlated with hs-CRP and cTnI levels (r = 0.422, 0.491, P < 0.05), and sTLT-1 levels were positively correlated with hs-CRP and cTnI levels (r = 0.404, 0.520, P < 0.05). When the diagnostic threshold of HMGB1 were 79.75 μg/L, the sensitivity and specificity of HMGB1 were 0.719 and 0.759. When the diagnostic threshold of sTLT-1 was 595.72 pg/mL, the sensitivity was 0.544 and the specificity was 0.794. The sensitivity and specificity of the two indexes were 0.842 and 0.858. Conclusion Elevated serum HMGB1 and sTLT-1 levels in AMI patients after PCI are also risk factors for the occurrence of MACE in the near future after PCI. Early combined detection can effectively predict the occurrence of MACE in AMI patients after PCI.
|
|
|
|
|
|
[1] 贺旭东，孙明辉，王志超，等.老年急性心肌梗死患者中血清白细胞介素-6、心肌肌钙蛋白Ⅰ、超敏C反应蛋白与肿瘤坏死因子-α水平的变化及临床意义[J].中国老年学杂志，2018，38（6）：1326-1328.
[2] 陈涛，高菊花.血清IL-6、hs-CRP和TNF-α水平在急性心肌梗死患者中的表达及相关性研究[J].河北医药，2018， 40（24）：3725-3728.
[3] 王东杰.急性心肌梗死患者IL-6、TNF-α、INF-γ、VEGF、Fg、hs-CRP水平变化及其与介入治疗关系的研究[J].国际检验医学杂志，2019，40（6）：750-753.
[4] 阚福强，聂宏刚.高迁移率族蛋白1与心血管疾病相关性的研究进展[J].心血管康复医学杂志，2019，28（3）：379-382.
[5] 高翔宇，陈晖，王萍，等.高迁移率族蛋白1在心血管疾病中的研究进展[J].临床和实验医学杂志，2015，14（4）：339-342.
[6] 庞睿娟.急性脑梗死患者血清CD62P、sTLT-1和ET-1的表达水平及临床意义探讨[J].检验医学与临床，2019，16（17）：2484-2486.
[7] Fu R，Song X，Su D，et al. Serum STLT-1 and bilirubin levels in patients with acute coronary syndrome and correlation with prognosis [J]. Exp Ther Med，2018，16（1）：241-245.
[8] Pelham CJ，Pandya AN，Agrawal DK. Triggering receptor expressed on myeloid cells receptor family modulators：a patent review [J]. Expert Opin Ther Pat，2014，24（12）：1383-1395.
[9] 刘晓红，李为民.残余SYNTAX评分对急性心肌梗死患者经皮冠状动脉介入治疗术后不良预后的预测价值[J].中国介入心脏病学杂志，2019，27（8）：440-446.
[10] 高润霖.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志，2001（12）：9-24.
[11] Reed GW，Rossi JE，Cannon CP. Acute myocardial infarction [J]. Lancet，2017，389（10 065）：197-210.
[12] 米亚非，薛迎生，江建军，等.2001年至2011年台州医院急性心肌梗死数据的回顾性分析[J].中华老年心脑血管病杂志，2016，18（4）：367-371.
[13] 陈鸿涛.经皮冠状动脉介入联合替格瑞洛治疗急性心肌梗死的临床疗效研究[J].中国医药指南，2019，17（17）：138-139.
[14] 高科.心脏型脂肪酸结合蛋白、肌钙蛋白I联合脑钠肽在急性心肌梗死早期诊断中应用价值[J].中外医学研究，2018，16（30）：52-53.
[15] 高翔宇，李卫萍，贺毅，等.急性心肌梗死缺血/再灌注损伤的机制及其药物防治进展[J].临床和实验医学杂志，2019，18（20）：2237-2240，后插1.
[16] 初巍巍，李一代，唐兆杰，等.IL-6和hs-CRP在2型糖尿病合并不同类型冠心病患者中的检测意义[J].中国现代医生，2018，56（9）：28-30.
[17] 赵艳华，曾令恒，何思杰，等.高敏感肌钙蛋白I在诊断急性心肌梗死中的临床诊断界值分析[J].中国医药科学，2018，8（11）：104-106，149.
[18] 韩敏，沈清，邵周俊，等.超敏肌钙蛋白Ⅰ在急诊胸痛患者急性心肌梗死早期预测中的价值[J].中国医药导报，2019，16（3）：16-21.
[19] Jung C，Kelm M，Nitschmann S. PCI strategies in patients with acute myocardial infarction and cardiogenic shock ：CULPRIT-SHOCK[J]. Internist （Berl），2018，59（5）：514-516.
[20] 常光明，陈潇，耿鑫.高迁移率族蛋白B1在血管性痴呆中的炎性作用机制及研究进展[J].国际检验医学杂志，2019，40（15）：1893-1896.
[21] Feng L，Yang J，Liu W，et al. Lipid biomarkers in acute myocardial infarction before and after percutaneous coronary intervention by lipidomics analysis [J]. Med Sci Monit，2018，24：4175-4182.
[22] 边娟，孙红梅，李飞.早发冠心病的相关血清学标志物研究进展[J].山东医药，2019，59（21）：112-114.
[23] 岳颖.急性心肌梗死患者联合检测血清钠尿肽、肌钙蛋白Ⅰ的意义[J].黑龙江医药科学，2017，40（4）：106-107.
[24] 章春，冯健，李家富.高迁移率族蛋白B1与心室重构[J].实用医学杂志，2014，30（13）：2166-2168.
[25] 金鹏，周琪，康美丽，等.早期HMGB1水平与AMI患者行急诊PCI院内发生心力衰竭的相关性[J].心脏杂志，2017，29（4）：431-434. |
|
|
|
